On Jan. 05, Trizzino John divested U.S. $2,012,353 in shares of Novavax Inc.. The EVP, CMO, CBO sold 17,913 shares at a price per share of $112.34. The transaction decreased this specific insider’s holdings to 287 shares worth around $36787.66 at present.
Jefferies launched its Novavax Inc. [NVAX] rating to the equivalent of a Buy and assigned the price target of $200, in a research note dated December 14, 2020. That figure represents around a 35.91% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Jefferies’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid December. Meanwhile, H.C. Wainwright had maintained its rating on NVAX to the earlier “Buy” rating, in a research note produced for clients August 06, 2020. In addition, there was an upgrade from JP Morgan on August 05, 2020. The rater changed NVAX from “a Neutral” to “an Overweight”.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Is Novavax Inc. [NASDAQ:NVAX] a Good Buy Right Now?
It should be noted that NVAX technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 56% Buy in the last week and compares with 72% Buy in the past month. Data from Novavax Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 3.99 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 4.33 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 4.55 million shares.
NVAX Price Performance
On Wall Street, Novavax Inc. [NASDAQ:NVAX] finished Thursday’s session up 3.59% at $128.18. The stock went up to $129.95 at the same session while its lowest single day price was $124.03. In the last five days, it saw a rise of about 7.75%, Novavax Inc. shares gained by almost 14.95% since the beginning of the year. However, the share price has dropped to as low as -32.32% below its one year high. On 01/07/21, the company shares recorded $129.95, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $109.01. The company’s shares have inclined by 2894.86% in the past year. The 50-day SMA achieved is $108.04 while the 200-day SMA is $87.78. Volume dropped to 2.92 million from 3.2 million in the previous session.
NVAX Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 124.82 level, and in case of violation of this particular level, it will cause more drop to 121.47 level. On the upper level, 133.31 is still the key resistance. The stock may increase to the subsequent resistance at 130.74. The Relative Strength Index (RSI) pinned on the 14-day chart is 56.97, implying a neutral technical stance while the MACD stands at 1.17, meaning price will increase in the next trading period. Percent R indicator moved to 17.51%, implying bullish price movement. Stochastic %K at 61.14% suggest holding the stock.
What is the short interest in Novavax Inc.?
Short interest in the Novavax Inc. stock has surged, increasing by 1.48 million shares to total 7.23 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.71 million, data from Yahoo Finance shows. The decrease of -20.47% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 11.40% of the overall float for the stock.
Novavax Inc.’s Biggest Shareholders: Who Owns Novavax Inc. [NVAX]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 5,307,429 shares or roughly 8.34% of the outstanding NVAX shares. This means their shares have increased by 789,322 from the 5,307,429 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, BlackRock Fund Advisors updated stake is worth $510,722,892. Details in the latest 13F filings reveal that Franklin Advisers, Inc. disposed off their -25.37% stake valued at $313,096,869 while SSgA Funds Management, Inc. cut theirs at $238,385,831. During the last quarter, Franklin Advisers, Inc. liquidated -763,002 of its shares in Novavax Inc. while SSgA Funds Management, Inc. sold -604,488 shares. The RA Capital Management LP’s holdings currently number 1,198,602 shares at $153636804.36. According to the firm’s last 13F report, Capital Research & Management Co shares in the company at filing stood at 1,156,379 shares, roughly $161,314,871.
NVAX Earnings Forecast For The Current Quarter
Novavax Inc. [NVAX] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $347.92M and an earnings per share of -$1.31 for Dec 2020. Looking further ahead, the company is expected to report revenue of $763.91M at an EPS of $3.04 for Mar 2021. The estimates represent upside of 463.40% and 421.30% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
NVAX Earnings Estimates For The Current Year
For the financial year, Novavax Inc. [NASDAQ:NVAX] is expected to bring in revenue of $543.87M. The returns are nearly $525.21 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -5.49, higher than that of FY19 by $0.02. Estimates put this year’s earnings growth at 0.40%, 421.30% for the next. As for sales, forecasts are for an increase of 2,814.30% in the current fiscal year and a further 463.40% over the following year.
What are analyst thoughts on Novavax Inc.?
Looking forward to the Novavax Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Novavax Inc. stock at $209.00 within the next 12 months, which represents almost 38.67 per cent growth from its previous closing price of $128.18. The highest analysts’ target for Novavax Inc. stock projections is $223.00 and the lowest one is $75.00. Still, 7 analysts sharing their consensus rating for NVAX stock in 2021 agree that it is an Overweight.